Spinosad blocks CHRNA5 mediated EGFR signaling pathway activation to inhibit lung adenocarcinoma proliferation

doi:10.1016/j.biopha.2024.117105

科研成果详情

题名	Spinosad blocks CHRNA5 mediated EGFR signaling pathway activation to inhibit lung adenocarcinoma proliferation
作者	Zou, Hongling 1,2; Chen, Yan 3; Zhu, Xinping 2; Zhao, Xinyun 1,2; Cao, Jili 2; Chen, Yuxin 2,4; Zhang, Ziru 2,4; Zhu, Yongqiang 2; Li, Qun 1; Li, Mingqian 2,4
发表日期	2024-08
发表期刊	BIOMEDICINE & PHARMACOTHERAPY 影响因子和分区
语种	英语
原始文献类型	Article
关键词	LUAD nAChR Spinosad CHRNA5 EGFR
其他关键词	NICOTINIC ACETYLCHOLINE-RECEPTORS ; GROWTH-FACTOR-RECEPTOR ; SYSTEMIC THERAPY ; CANCER ; PROTEIN ; PHOSPHORYLATION ; ERLOTINIB ; SMOKING ; SITES ; CELLS
摘要	Lung adenocarcinoma (LUAD) is the leading cause of cancer death worldwide, with high incidence and low survival rates. Nicotinic acetylcholine receptors play an important role in the progression of LUAD. In this study, a screening of 17 nicotinic acetylcholine receptor allosteric agents revealed that spinosad effectively suppressed the proliferation of LUAD cells. The experiments demonstrated that spinosad induced cell cycle arrest in the G1 phase and stimulated apoptosis, thereby impeding the growth of LUAD and enhancing the responsiveness to gefitinib in vitro and vivo. Mechanistic insights obtained through transcriptome sequencing, Co-IP, and protein immunoblots indicated that spinosad disrupted the interaction between CHRNA5 and EGFR, thereby inhibiting the formation of downstream complexes and activation of the EGFR signaling pathway. The supplementation of exogenous acetylcholine showed to mitigate the inhibition of LUAD cell proliferation induced by spinosad. This study elucidates the therapeutic effects and mechanisms of spinosad in LUAD, and offers a theoretical and experimental foundation for novel LUAD treatments.
资助项目	Medicine; Co-construction of Key Laboratory of Research on Prevention and Treatment for depression syndrome [GZY-ZJ-SY-2402]
出版者	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
ISSN	0753-3322
EISSN	1950-6007
卷号	177
DOI	10.1016/j.biopha.2024.117105
页数	13
WOS类目	Medicine, Research & Experimental ; Pharmacology & Pharmacy
WOS研究方向	Research & Experimental Medicine ; Pharmacology & Pharmacy
WOS记录号	WOS:001271799600001
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
PubMed ID	39002438
SCOPUSEID	2-s2.0-85198324122
通讯作者地址	[Li, Qun]Sichuan Normal Univ, Coll Life Sci, Chengdu 610101, Sichuan, Peoples R China. ; [Li, Mingqian]Tongde Hosp Zhejiang Prov, Canc Inst Integrated Tradit Chinese & Western Med, Zhejiang Acad Tradit Chinese Med, Hangzhou 310012, Zhejiang, Peoples R China.
Scopus学科分类	Pharmacology
TOP期刊	TOP期刊
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/216759
专题	其他_附属诸暨医院（诸暨市人民医院）
通讯作者	Li, Qun; Li, Mingqian
作者单位	1.Sichuan Normal Univ, Coll Life Sci, Chengdu 610101, Sichuan, Peoples R China; 2.Tongde Hosp Zhejiang Prov, Canc Inst Integrated Tradit Chinese & Western Med, Zhejiang Acad Tradit Chinese Med, Hangzhou 310012, Zhejiang, Peoples R China; 3.Wenzhou Med Univ, Zhuji Peoples Hosp, Zhuji 311899, Zhejiang, Peoples R China; 4.Hangzhou Med Coll, Hangzhou 310059, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Zou, Hongling,Chen, Yan,Zhu, Xinping,et al. Spinosad blocks CHRNA5 mediated EGFR signaling pathway activation to inhibit lung adenocarcinoma proliferation[J]. BIOMEDICINE & PHARMACOTHERAPY,2024,177.
APA	Zou, Hongling., Chen, Yan., Zhu, Xinping., Zhao, Xinyun., Cao, Jili., ... & Li, Mingqian. (2024). Spinosad blocks CHRNA5 mediated EGFR signaling pathway activation to inhibit lung adenocarcinoma proliferation. BIOMEDICINE & PHARMACOTHERAPY, 177.
MLA	Zou, Hongling,et al."Spinosad blocks CHRNA5 mediated EGFR signaling pathway activation to inhibit lung adenocarcinoma proliferation".BIOMEDICINE & PHARMACOTHERAPY 177(2024).